Antibodies News and Research

RSS

Potential mosquito-based malaria vaccine could be a step closer

A promising type of vaccine designed to eradicate malaria by blocking parasite transmission could be a step closer, as a result of experts uncovering new information about the targeted protein.

17 Jun 2015

CytomX closes $70 million Series D financing round

CytomX, a biotechnology company developing Probody™ therapeutics for the treatment of cancer, today announced the closing of a $70 million Series D financing round. The financing was led by Fidelity Management & Research Company with participation from Casdin Capital, Cormorant Asset Management, Deerfield Management, Perceptive Advisors, Redmile Group, Tekla Healthcare Investors and Tekla Life Sciences Investors, Venrock Healthcare Capital Partners, Wellington Management Company and additional undisclosed investors.

17 Jun 2015

Researchers locate promising target for potential vaccine against malaria

Researchers from the Johns Hopkins Bloomberg School of Public Health have located a new - and likely more promising, they say - target for a potential vaccine against malaria, a mosquito-borne illness that kills as many as 750,000 people each year.

16 Jun 2015

Apexigen initiates APX005M Phase 1 clinical trial in adults with solid tumors

Apexigen, Inc., a biopharmaceutical company discovering and developing innovative antibody drugs for the treatment of cancer and other life-threatening diseases, announced today the initiation of a Phase 1 clinical trial of APX005M, the company's lead proprietary anticancer program.

16 Jun 2015

OncoSec enrolls first patient in Phase II trial of ImmunoPulse IL-12 for treatment of HNSCC

OncoSec Medical Inc., a company developing DNA-based intratumoral cancer immunotherapies, announced today that the company has enrolled the first patient into OMS-I130, a Phase II clinical trial of ImmunoPulse IL-12 in patients with treatment-refractory, metastatic and unresectable squamous cell carcinoma of the head and neck (HNSCC).

16 Jun 2015

Stony Brook University, CadheRx Therapeutics sign licensing agreement for anti-cancer technology

Stony Brook University has entered into a licensing agreement with a startup company, CadheRx Therapeutics, to develop and market an anti-cancer technology discovered by Sabine Brouxhon, MD, Clinical Associate Professor in the Department of Emergency Medicine at Stony Brook University School of Medicine.

16 Jun 2015

Modifying small white blood cells may help treat immune disorders

Modifying the small white blood cells that protect against disease might help treat immune disorders, according to a study published in Cellular and Molecular Gastroenterology and Hepatology, the basic science journal of the American Gastroenterological Association.

16 Jun 2015

Novasep announces launch of BioSC Lab for protein purification

Novasep, a leading supplier of manufacturing solutions to the life science industries, today announces the launch of BioSC Lab, the next-generation low pressure chromatography equipment for the biopharmaceutical industry.

15 Jun 2015

Mesothelioma.us releases new case study that focuses on experimental treatments for mesothelioma

Mesothelioma.us, an educational and authoritative website that offers free and in-depth resources for mesothelioma patients and their families, has just released a new case study that focuses on the experimental treatments for the disease.

15 Jun 2015

Better way to predict survival in patients with HPV-positive oropharyngeal cancer

According to Sturgis, the incidence of HPV-positive oropharyngeal carcinoma has increased dramatically in recent years. Although patients with HPV-positive disease have a better prognosis than those with HPV-negative disease, researchers are still seeking a better understanding of what group of patients is more likely to respond to treatment.

15 Jun 2015

LMU clinicians reveal mechanism involved in determining lifetime of antibody-producing cells

Clinicians at Ludwig-Maximilians-Universitaet in Munich have elucidated a mechanism involved in determining the lifespan of antibody-producing cells, and identified a promising new biomarker for monitoring autoimmune diseases like multiple sclerosis and lupus erythematosus.

15 Jun 2015

Experimental drug improves failing heart's function

An experimental drug improves the ability of heart muscle cells damaged by heart failure to pump blood, according to the results of a study led by Icahn School of Medicine at Mount Sinai researchers and published online today in Nature Communications.

14 Jun 2015

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

This week, Lancet Oncology reports results of a 1,093-person phase III clinical trial of the drug necitumumab (IMC-11F8) combined with chemotherapies gemcitabine and cisplatin against stage IV squamous non-small cell lung cancer. With addition of necitumumab, median overall survival was 11.5 months compared with median survival of 9.9 months with the two chemotherapies alone.

11 Jun 2015

Purdue University-led analysis finds that carotenoid levels in breast milk differ by country, dietary habits

A Purdue University-led analysis of breast milk concludes that levels of health-promoting compounds known as carotenoids differ by country, with the U.S. lagging behind China and Mexico, a reflection of regional dietary habits.

11 Jun 2015

Creative Diagnostics announces launch of antibody generation service based on DNA immunization technology

Creative Diagnostics, the global diagnostics service and product supplier, is pleased to announce its launch of custom antibody production service based on DNA immunization technology. This DNA immunization technology allows high success rate in generation of high-affinity antibodies recognizing difficult-to-express proteins in their native confirmation, such as GPCRs, ion channels and other multiple membrane spanning proteins.

10 Jun 2015

MIPT researchers develop ultrasensitive nanomechanical sensor to identify tumor markers

Two young researchers working at the MIPT Laboratory of Nanooptics and Plasmonics, Dmitry Fedyanin and Yury Stebunov, have developed an ultracompact highly sensitive nanomechanical sensor for analyzing the chemical composition of substances and detecting biological objects, such as viral disease markers, which appear when the immune system responds to incurable or hard-to-cure diseases, including HIV, hepatitis, herpes, and many others.

10 Jun 2015

Apitope's ATX-F8-117 granted FDA Orphan Drug Designation for treatment of haemophilia A patients

Apitope, the drug discovery and development company focused on disease-modifying treatments that reinstate immune tolerance, announced today that pre-clinical product candidate ATX-F8-117 has been granted Orphan Drug Status by the US Food and Drug Administration for the prevention or treatment of inhibitors in haemophilia A patients with inhibitors or at the risk of producing inhibitors.

9 Jun 2015

Protective antibody response could be effective in preventing mother-to-child HIV transmission

How most babies are protected from acquiring HIV from their infected mothers has been a matter of scientific controversy.

9 Jun 2015

PQBP1 protein could improve body's immune response to HIV vaccines

In a scientific discovery that has significant implications for preventing HIV infections, researchers at Sanford-Burnham Medical Research Institute have identified a protein that could improve the body's immune response to HIV vaccines and prevent transmission of the virus.

5 Jun 2015

University of Chicago scientists develop new technique to accurately measure epigenetic changes

One of the most widely used tools in epigenetics research - the study of how DNA packaging affects gene expression - is chromatin immunoprecipitation (ChIP), a technique that allows researchers to examine interactions between specific proteins and genomic regions. However, ChIP is a relative measurement, and has significant limitations that can lead to errors, poor reproducibility and an inability to be compared between experiments.

4 Jun 2015

Antibodies News and Research

Potential mosquito-based malaria vaccine could be a step closer

CytomX closes $70 million Series D financing round

Researchers locate promising target for potential vaccine against malaria

Apexigen initiates APX005M Phase 1 clinical trial in adults with solid tumors

OncoSec enrolls first patient in Phase II trial of ImmunoPulse IL-12 for treatment of HNSCC

Stony Brook University, CadheRx Therapeutics sign licensing agreement for anti-cancer technology

Modifying small white blood cells may help treat immune disorders

Novasep announces launch of BioSC Lab for protein purification

Mesothelioma.us releases new case study that focuses on experimental treatments for mesothelioma

Better way to predict survival in patients with HPV-positive oropharyngeal cancer

LMU clinicians reveal mechanism involved in determining lifetime of antibody-producing cells

Experimental drug improves failing heart's function

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

Purdue University-led analysis finds that carotenoid levels in breast milk differ by country, dietary habits

Creative Diagnostics announces launch of antibody generation service based on DNA immunization technology

MIPT researchers develop ultrasensitive nanomechanical sensor to identify tumor markers

Apitope's ATX-F8-117 granted FDA Orphan Drug Designation for treatment of haemophilia A patients

Protective antibody response could be effective in preventing mother-to-child HIV transmission

PQBP1 protein could improve body's immune response to HIV vaccines

University of Chicago scientists develop new technique to accurately measure epigenetic changes

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo